Health economist & policy expert

Health economics, policy, pharmaceuticals, health care systems. Oh, and a little bit about life in general.

  • 105
    stories
  • 70K
    words
105
stories for
7
publications
Leela Barham's stories for
Show all
pharmaphorum.com

Behind the buzz of real-world data and real-world evidence ...

Behind the buzz of real-world data and real-world e...

pharmexec.com

Pharmaceutical Executive

A tale of two pricing schemes

pharmexec.com

Pharmaceutical Executive

NICE sets out proposed technology assessment fees

eyeforpharma

Market access: How to meet both marketing authorisation and HTA ...

Jul 13, 2010 ... Leela Barham looks at the costs and benefits of taking a more collaborative approach towards marketing authorisation and Health Technology ......

James 1 8x10 copy article
eyeforpharma

Scotland: Doing Things Differently | Thought leadership and ...

Scotland: Doing Things Differently. By Leela Barham on May 29, 2015. Doubling of Scottish New Medicines Fund: Good or Bad? James Barrow, Head of ......

Data 0 article
eyeforpharma

Year in Review 2014: Market Access | Thought leadership and ...

Dec 22, 2014 ... Leela Barham examines key features of the EMA's Adaptive Licensing pilot, and the MHRA's Early Access to Medicines Scheme. “The schemes ......

diabetesandprimarycare.co.uk

View Issue - 2014, Vol 16, No 6, pages 273–320

Spending on prescribing for diabetes in England: A holistic perspective. Page 286 Author: Leela Barham · FULL TEXT PREVIEW PDF Add to reading list ......

Housesofparliament article
pharmexec.com

What Does the UK's "New" Government Mean for the Industry?

Following the Conservatives surprise majority win in the UK election, Leela Barham asks what does it mean for pharma?...

pharmexec.com

New European Guidelines Tackle Controversial HTA Components

EUnetHTA has developed guidelines to help “set a general framework for EUnetHTA on how to conduct economic evaluations”, arguably HTA's most controversial element. Leela Barham reports....

pharmexec.com

Tougher Times Ahead Under UK PPRS

Under the voluntary 2014 Pharmaceutical Price Regulation Scheme in the UK, member companies have to pay back if NHS spending on branded medicines goes over pre-agreed growth rates. With no growth allowed for 2014 and 2015, it was always going to be a matter of when and how much —...

pharmexec.com

UK: The PPRS is Dead, Long Live the PPRS! | Pharmaceutical ...

UK: The PPRS is Dead, Long Live the PPRS! Nov 06, 2013. By Leela Barham. Pharmaceutical Executive. Long awaited details have been announced in the ......

pharmexec.com

first

Following the Conservatives surprise majority win in the UK election, Leela Barham asks what does it mean for pharma? Welcome to the HTA Jungle. May 01 ......

pharmexec.com

Pharmaceutical Executive-06-01-2015 | Pharmaceutical Executive

What Does the UK's "New" Government Mean for the Industry? By Leela Barham. Examining the fallout for pharma after the Conservatives surprise majority win....

pharmexec.com

The NHS's Meningitis B Vaccine Deal with GSK: A Slow Step in the Right Direction

That the UK's NHS has struck a deal for a national roll-out of Bexsero, GSK's vaccine for Meningitis B in infants, is good, but it needs to do better, writes Leela Barham....

Leela barham pharma 200x200 article
pharmaphorum.com

Real world cost effectiveness: lessons from the MS risk sharing scheme

Real world cost effectiveness data is in high demand, but how easy is it to find and assess in practice? Leela Barham investigates the pros and cons through an examination of the MS risk sharing scheme, which has been running since 2002. Interest......